Attached files

file filename
8-K - FORM 8-K - Shire plcdp74862_8k.htm

 

Exhibit 99.1

 

Press Release  
www.shire.com  

 

 

Director/PDMR Shareholding

 

April 4, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

 

Notification of transactions by person discharging managerial responsibilities

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”)
a) Name Flemming Ornskov
2. Reason for the notification
a) Position / status Chief Executive Officer - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Release of ADSs awarded under the Shire Executive Annual Incentive on March 31, 2014. In accordance with the relevant plan rules, upon release the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the ADSs from the award date to the date of release.

 

(Details of related disposals of ADSs are referenced in sections 5. – 10. and the appendix below.)

 

c) Price(s) and volume(s) Price(s) Volume(s)
N/A 2,735
d)

Aggregated information

- Aggregated volume 

- Price

N/A (single transaction)
e) Date of the transaction March 31, 2017
f) Place of the transaction N/A

 

5. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

 

(See appendix below for aggregate disposal details.)

c) Price(s) and volume(s) Price(s) Volume(s)
$174.93 2
$175.10 5
$175.28 10
$175.28 100
$175.27 100
$175.13 100
$175.23 100
$175.18 100
d)

Aggregated information

- Aggregated volume 

- Price

Weighted average price Aggregate volume

$175.22

517

e) Date of the transaction March 31, 2017
f) Place of the transaction ARCX
6. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

 

(See appendix below for aggregate disposal details.)

 

c) Price(s) and volume(s) Price(s) Volume(s)
$175.35 100
$175.30 100
$175.34 100
$175.28 100
$175.28 100
$175.30 100
d)

Aggregated information

- Aggregated volume 

- Price

Weighted average price Aggregate volume

$175.31

600

e) Date of the transaction March 31, 2017
f) Place of the transaction DBAX
7. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

 

(See appendix below for aggregate disposal details.)

c) Price(s) and volume(s) Price(s) Volume(s)
$175.31 100
$175.31 100
$175.29 100
d)

Aggregated information

- Aggregated volume 

- Price

Weighted average price Aggregate volume

$175.30

300

e) Date of the transaction March 31, 2017
f) Place of the transaction IEXG

 

8. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

 

(See appendix below for aggregate disposal details.)

c) Price(s) and volume(s) Price(s) Volume(s)
$175.11 100
d)

Aggregated information

- Aggregated volume 

- Price

N/A (single transaction)

 

e) Date of the transaction March 31, 2017
f) Place of the transaction BOSX
9. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

 

(See appendix below for aggregate disposal details.)

c) Price(s) and volume(s) Price(s) Volume(s)
$175.27 100
d)

Aggregated information

- Aggregated volume 

- Price

N/A (single transaction)

 

e) Date of the transaction March 31, 2017
f) Place of the transaction CSDK

 

10. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Automated disposal of ADSs in relation to the release of ADSs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the release of the ADSs.

 

(See appendix below for aggregate disposal details.)

c) Price(s) and volume(s) Price(s) Volume(s)
$175.18 100
d)

Aggregated information

- Aggregated volume 

- Price

N/A (single transaction)

 

e) Date of the transaction March 31, 2017
f) Place of the transaction EDGX

 

Appendix

 

Place of the transaction Aggregate volume Weighted average price
ARCX 517 $175.22
BOSX 100 $175.11
CSDK 100 $175.27
DBAX 600 $175.31
EDGX 100 $175.18
IEXG 300 $175.30
Total 1,717 $175.26

 

 

Oliver Strawbridge

Senior Assistant Company Secretary

 

For further information please contact:

 

Investor Relations    
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media    
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com   +1 617 949 9083

 

NOTES TO EDITORS

 

About Shire

 

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com